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Abstract
Introduction The effectiveness of valproate (VPA) in the
treatment of focal and generalized epilepsies is well
established. The drug has a wide spectrum of action, good
tolerability, and has been available as an injectable for-
mulation since 1993. Despite the lack of class A evidence,
it has been used extensively in various forms of status
epilepticus (SE).
Aim Our aim was to present a systematic review of data
from randomized and non-randomized controlled trials to
evaluate the efficacy and safety of intravenous VPA for the
treatment of SE.
Methods Data sources included MEDLINE, back tracing
of references in pertinent studies, and contact with the
manufacturer of VPA (Sanofi-Aventis).
Results Overall, the search strategy yielded 433 results
(425 MEDLINE, seven congress abstracts, one unpub-
lished study); after excluding duplicate publications and
case reports, 30 studies were identified (the earliest was
published in 1993, the most recent in 2012); ten were
controlled (six randomized controlled trials, four non-ran-
domized controlled studies), and 20 uncontrolled trials
(eight prospective observational studies, 12 retrospective
case series). The cumulative literature describes the expe-
riences of 860 patients with various forms of SE treated
with intravenous VPA. The overall response rate to abro-
gate SE was 70.9 % (601/848; 95 % confidence interval
[CI] 67.8–73.9). Response rates to intravenous VPA were
better in children than in adults and did not differ between
the SE types. The most commonly reported effective doses
were between 15 and 45 mg/kg in bolus (6 mg/kg/min)
followed by 1–3 mg/kg/h infusion. Safety studies of
intravenous VPA administration in patients with SE
showed a low incidence of adverse events overall (\10 %),
mainly dizziness, thrombocytopenia, and mild hypoten-
sion, which was independent of infusion rates. Of note,
good cardiovascular and respiratory tolerability was
observed in these studies, even at high doses and fast
infusion rates (up to 30 mg/kg at 10 mg/kg/min), despite
multiple morbidities or other antiepileptic drugs. The most
serious concern relates to the possibility of acute enceph-
alopathy, sometimes related to hepatic abnormalities or
hyperammonemia.
Conclusions The published experience is consistent
with VPA being a safe and effective therapeutic option
for patients with established SE who have previously
failed conventional first-line treatment with benzodi-
azepines, but high-quality randomized controlled trials
are needed to inform clinicians on its comparative
effectiveness in SE.
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Key Points
The overall response rate to abrogate status
epilepticus (SE) with intravenous (IV) valproate was
70.9 % (601 out of 848 patients; 95 % confidence
interval [CI] 67.8–73.9), with a most commonly used
dose between 15 and 45 mg/kg in bolus (6 mg/kg/
min) followed by 1–3 mg/kg/h infusion.
The incidence of adverse events was low overall
(\10 %), mainly dizziness, thrombocytopenia, and
mild hypotension, which was independent of
infusion rates, and a good cardiovascular and
respiratory tolerability even in high doses and fast
infusion rates up to 30 mg/kg at 10 mg/kg/min.
Given the low incidence of clinically relevant
adverse events, and the potentially serious or even
fatal consequences of not abrogating seizure activity
rapidly in SE, the ratio of benefit to risk seems
clearly in favor of treatment.
Though IV valproate appears to be an effective and
safe treatment with good tolerability in SE, there is
an urgent need for high-quality randomized
controlled trials to inform clinicians on the best
treatment in SE.
1 Introduction
Status epilepticus (SE) can be defined as ‘‘a condition
characterized by an epileptic seizure that is so frequent or
so prolonged as to create a fixed and lasting condition’’ [1].
In light of the seriousness of the condition and the urge to
treat as early as possible to prevent refractory SE, the
timeframe has been progressively shortened to a pragmatic
definition of 5 min ongoing seizures [2]. Indeed, if left
untreated, SE is potentially fatal or can lead to irreversible
brain damage. Population-based studies [3–8] have esti-
mated an incidence of up to 60 cases per 100,000 per year,
with the highest incidence in young children and the
elderly [9]. Thus, it represents one of the most common
neurological emergencies.
There is general agreement that treatment of SE should
follow a staged treatment protocol [10]. Randomized
controlled trials show that intravenous lorazepam [11–13]
or intramuscular midazolam [14, 15] are the most efficient
treatment in early status. Approximately 30–40 % of all
patients fail to respond to initial treatment with benzodi-
azepines and need further treatment with intravenous
antiepileptic drugs (AEDs). A high proportion of these
remain refractory, necessitating the use of anesthetics [12,
16–18]. Intravenous phenytoin or phenobarbital is widely
used as treatment for established status. However, these
drugs are not efficacious in several epilepsy syndromes and
there are tolerability issues associated with their use. Both
phenobarbital and phenytoin may cause cardiac arrhyth-
mias, hypotension, and respiratory depression, the latter
being aggravated by co-administration with benzodiaze-
pines [17].
Intravenous formulations of other AEDs, including
valproate, levetiracetam, and lacosamide have generated
considerable interest in their potential use for the treatment
of established SE after failure of benzodiazepines [19–22].
The first case reports demonstrating the utility of valproate
administered rectally for controlling SE go back to the late
1970s [23–26] and continued to be described throughout
the 1980s and 1990s [27] until intravenous valproate was
introduced [19, 28].
The fact that SE generally occurs without warning, and
the need to treat SE as a medical emergency, means that
classical randomized clinical trials corresponding to con-
temporary regulatory standards are extremely challenging
to perform. Thus, there are no class I data to support
treatment recommendations on the choice of AED for
established and refractory SE. Nonetheless, the published
literature contains extensive information on the efficacy
and safety of intravenous valproate in the treatment of SE,
which has been used as the basis for regulatory approval of
this treatment in such selected countries as Norway and
Germany.
This article provides a systematic literature review of
the current evidence for the efficacy and tolerability of
valproate in the treatment of SE.
2 Methods
A comprehensive review of the literature and searches to
find unpublished trials was performed to minimize publi-
cation bias. The electronic database MEDLINE (January
1966–19 March 2013; accessed by PubMed) was compre-
hensively searched. The medical subject heading (MeSH)
terms ‘valproic acid’ and ‘status epilepticus’, as well as the
following free terms were used in multiple search strategies
with Boolean operators to find relevant articles published
until 19th March 2013: ‘valproate’, ‘valproic acid’, and
‘status epilepticus’.
The following search strategy was applied: ((‘valproic
acid’ [MeSH] OR valpro* OR valproic acid OR valproate)
AND (‘status epilepticus’ [MeSH] OR status epilepticus)).
All resulting titles and abstracts were evaluated, and any
relevant article was considered. There were no language
restrictions.
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All identified studies were cross referenced to identify
any reports that may have been missed. The manufacturer
of valproate (Sanofi-Aventis) was asked for any reports of
further unpublished studies. For the analysis of efficacy,
case reports were excluded, since it is not possible to
determine response rates from individual cases. For the
same reason, studies in which multiple AEDs were
evaluated without presentation of results for individual
AEDs were also excluded. Studies using intravenous
valproate as first-line treatment or after failure of first-line
benzodiazepines (lorazepam or diazepam) were consid-
ered eligible. For each study, response rates were
extracted as the proportion of patients whose seizures
resolved after valproate treatment. Seizure resolution was
most frequently adopted in the studies as outcome for
efficacy. However, cessation of seizure activity, or AED
efficacy, was defined differently by different authors in
the selected studies; some were based on termination of
seizures alone and others based on a lack of recurrence
for a certain period of time. Furthermore, in some studies,
seizure resolution was based on clinical signs alone and in
other studies on the assessment of electrographic seizure
activity.
The frequency of adverse events reported in the studies,
particularly hypotension and respiratory depression, was
used for the analysis of safety; the worldwide pharmaco-
vigilance database of Sanofi-Aventis was also interrogated
to identify reported adverse events.
3 Results
3.1 Studies Identified
The search strategy yielded 433 results (425 MEDLINE,
seven congress abstracts, one unpublished study). After
excluding duplicate publications and case reports, 55 arti-
cles were provisionally selected. We excluded 25 studies
after reading the full published papers; thus, 30 studies
contributed to this review: the earliest was published in
1993 and the most recent in 2012.
Overall, we identified through a comprehensive search
in MEDLINE 25 publications in which the efficacy of
intravenous valproate in SE had been reported [29–53].
Cross-referencing identified seven additional reports in
congress abstracts [54–60]. Three of these were redundant
[55, 57, 60] as they corresponded to case series subse-
quently described in full publications as part of larger
cohorts [35, 40, 45]. Finally, the manufacturer of valproate
provided the clinical study report of an unpublished study
[61].
Of the 30 unique studies identified, six were random-
ized controlled trials, none of them blinded, comparing
intravenous valproate to phenytoin, diazepam, or pheno-
barbital [41–43, 46, 52, 53], and four non-randomized
controlled studies comparing intravenous valproate to
phenytoin or levetiracetam [48–51]. One randomized
controlled trial also included patients with acute repetitive
seizures not entailing the diagnosis of SE. For this study,
information from patients with SE was obtained from a
systematic review [62]. Of the uncontrolled studies, eight
were prospective observational studies and 12 were retro-
spective case series.
3.1.1 Randomized Controlled Studies
Three randomized controlled studies compared intrave-
nous valproate with intravenous phenytoin [41, 42, 46],
two with intravenous diazepam [43, 52], and one with
intravenous phenobarbital [53]. These studies included
361 patients (183 were randomized to receive valproate;
Table 1; Fig. 1). The phenobarbital study [53] and one
diazepam study [43] included only children; one phenyt-
oin study [46] included only adults, whereas the remain-
ing studies [41, 42, 52] included all age groups. The most
frequent SE was generalized convulsive. Valproate was
administered most often at an initial bolus dose of 20 or
30 mg/kg (Table 2).
3.1.2 Non-Randomized Controlled Trials
Non-randomized controlled studies were included in the
present review. Two studies utilized a prospective design
[49, 50], and two were retrospective [48, 51]. These studies
included 455 subjects (197 were randomized to valproate;
Table 1).
3.1.3 Prospective Open-Label Studies
The eight prospective studies identified are presented in
Table 1. Overall, these included 191 patients with SE
treated with intravenous valproate (135 adults, 46 children,
and ten of unspecified age). These studies all evaluated
intravenous valproate administered in monotherapy, usu-
ally administered as a bolus (15–40 mg/kg) followed by a
maintenance infusion.
3.1.4 Retrospective Case Series
We identified 12 retrospective case series (Table 3). These
included 76 adults, 45 children, and 135 subjects of
unspecified age with SE. Again, valproate was usually
administered as a bolus (15–40 mg/kg) followed by a
maintenance infusion.
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3.2 Seizure Outcome
Response rates are presented in Table 4. These rates
varied across studies, between 35 and 100 % (median
74.35 %). The overall response rate in all studies was
70.9 % (601/848; 95 % confidence interval [CI]
67.8–73.9). Outcome in children (81.3 %; 104/128;
95 % CI 74.5–88) was better than in adults (68.5;
207/302; 95 % CI 63.3–73.8). Response rate was lower
in controlled non-randomized studies (61.8 %, 114/185;
95 % CI 54.6–66.6) than in randomized controlled
studies (75.4 %; 138/183; 95 % CI 69.2–81.6) or ret-
rospective case series (68.2 %; 197/289; 95 % CI
62.8–73.8). There was no difference in response rates in
convulsive (69.7 %; 246/353; 95 % CI 64.9–74.5)
compared with non-convulsive SE (75 %; 15/20; 95 %
CI 56–94), although the comparison is limited by the
small number of studies in which outcome was pre-
sented according to SE type.
3.2.1 Comparative Randomized Studies
Six studies have compared the efficacy of intravenous
valproate with that of intravenous phenytoin, diazepam, or
phenobarbital. Two studies compared valproate with phe-
nytoin in early SE [43, 46], whereas one study compared
valproate with phenytoin in established SE [42].
In the first study [41] comparing the rate of response,
defined as seizure cessation at the end of the infusion, it
was significantly (p = 0.046) higher in the valproate group
(66 %; n = 35) than in the phenytoin group (42 %;
n = 33). Non-responders were switched to the other
treatment, where 15 of 19 non-responders to phenytoin
(79 %) responded to valproate compared with 3 of 12 non-
responders to valproate (12 %) who responded to phenyt-
oin (p = 0.004). Seizure freedom at 24 h was obtained in
29 patients, irrespective of treatment group or sequence.
However, the use of a maintenance AED regimen after the
bolus infusion was not reported in this study.
Table 1 Randomized comparative studies evaluating intravenous
valproate monotherapy in the treatment of status epilepticus. Studies
are listed in decreasing order of sample size. All studies were carried
out as single-center open-label trials, except Malamiri et al., which
was conducted in two centers
References N Patients Type of SE Dose regimen
Agarwal et al. [42] V: 50, P: 50 62 adults/38 children





V: Initial bolus 20 mg/kg at 40 mg/min,
P: Initial bolus 20 mg/kg at up to
50 mg/min
Misra et al. [41] V: 35, P: 33 Adults and children




V: Initial bolus 30 mg/kg in 100 ml over
15 min, P: Initial bolus 18 mg/kg in
100 ml infused at 50 mg/min
Gilad et al. [46] V: 18, P: 9 Adults ([18 y), 19
male/7 female
GTC SE V : Initial bolus 30 mg/kg in 50 ml of
saline over 20 min, P: Initial bolus of
18 mg/kg in 100 ml of saline over
20 min
Chen et al. [47] V: 30, D: 36 Children and adults
([15 y), 36 male/
30 female
GTC and sGTC SE V: Initial bolus 30 mg/kg at 6 mg/kg/min
followed by continuous infusion at
1–2 mg/kg/h, D: Initial (third) bolus of
0.2 mg/kg at 5 mg/min followed by
infusion at 4 mg/h for 3 min and then
increased every 3 min by 1 lg/min until
seizure control or maximal duration
(1 h) reached
Mehta et al. [43] V: 20, D: 20 Children (B12 y)
(mean 3.7), 31
boys/9 girls
GTC SE: 18, sGTC
SE : 12, Simple
focal SE: 8,
Multifocal : 2
V: Initial bolus 30 mg/kg over 2–5 min;
if SE uncontrolled, repeat bolus then
infusion at 5 mg/kg/h, D: 10 lg/kg/min
initial infusion increased by 10 lg/kg/h










V: Initial bolus 20 mg/kg in 20 ml saline
at max. 5–6 mg/kg/min over 5–10 min,
B: Initial bolus 20 mg/kg at max.
60–100 mg/min
B phenobarbital, D diazepam, GTC generalized tonic–clonic, JME juvenile myoclonic epilepsy, P phenytoin, SE status epilepticus, sGTC
secondary generalized tonic–clonic, V valproate
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In the second study [46], treatment success was defined
as clinical seizure cessation after infusion without need for
rescue medication within 20 min of the infusion. No sta-
tistically significant difference in the rate of treatment
success was found among patients treated with valproate
(13 of 18; 72.2 %) and phenytoin (seven of nine patients;
77.8 %). Seizure freedom at 24 h was obtained in all
patients (100 %) in both groups.
In the study comparing valproate with phenytoin in
established SE, treatment success was defined as cessation
of all motor and electroencephalography (EEG) seizure
activity within 20 min of starting drug infusion and no
return of seizure activity in the following 12 h [42].
According to this criterion, 44 patients receiving valproate
(88 %) and 42 receiving phenytoin (84 %) experienced
treatment success. Success rates were higher in patients in
whom SE had been treated within 2 h (p \ 0.05), with only
one such patient treated with phenytoin failing to respond.
In the study comparing valproate with diazepam, both in
children and in adults, generalized convulsive SE was
controlled in 56 % (20 of 36 patients) of the diazepam
group and 50 % (15 of 30 patients) in the valproate group
[52]. Relapse of SE within 24 h occurred in 25 % (5 of 20
patients) of the diazepam and 20 % (3 of 15 patients) of the
valproate group. Both failed to reach statistical signifi-
cance, suggesting no differences between groups in terms
of efficacy.
A recent systematic review assessing the role of val-
proate in generalized convulsive SE included the above-
mentioned studies comparing intravenous valproate with
intravenous phenytoin [41, 42, 46] in a meta-analysis [62].
Compared with phenytoin, intravenous valproate had no
Fig. 1 Intravenous valproic
acid versus intravenous
phenytoin, and intravenous





Manager 5.2 (available at:
http://tech.cochrane.org/
revman/download). CI confi-
dence interval, DZP diazepam,
IV intravenous, PHT phenytoin,
VPA valproic acid
Table 2 Non-randomized comparative studies evaluating intravenous valproate monotherapy in the treatment of SE
References N Patients Type of SE Dose regimen
Tripathi et al. [49] V: 41, L: 41 Adults ([14 y),
42 male/40
female
Refractory GTC SE V: Initial bolus 30 mg/kg at 5 mg/kg/min,
L: initial bolus 30 mg/kg at 5 mg/kg/min
Tiamkao and
Sawanyawisuth [48]
V: 32, P: 37a Adults ([15 y),
No information
on gender
GTC SE V: Initial bolus 15–25 mg/kg with max infusion
rate of 50 mg/min, P: Initial bolus 15–20 mg/
kg with max infusion rate of 50 mg/min




GTC SE: 108, NCSE: 9 V: Initial bolus 30 mg/kg, P: Initial bolus 20 mg/
kg





SE (all subtypes including
NCSE)
V: Initial bolus 20 mg/kg with maintenance
dosage 1,000–2,500 mg/day, P: Initial bolus
20 mg/kg with maintenance dosage
300–400 mg/day, L: Initial bolus 20 mg/kg
with maintenance dosage 1,000–3,000/day
Studies are listed in decreasing order of sample size
a 12 and 20 patients received intravenous valproate as the first- and second-line therapy, respectively
GTC generalized tonic–clonic, L levetiracetam, NCSE non-convulsive status epilepticus, P phenytoin, SE status epilepticus, V valproate
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statistically significant differences in seizure cessation after
drug administration (risk ratio [RR] 1.31, 95 % CI
0.93–1.84) and in seizure freedom at 24 h (RR 0.96, 95 %
CI 0.88–1.06).
In the study comparing valproate with diazepam in
children, SE was successfully controlled in 16/20 patients
receiving valproate (80 %) and 17/20 patients receiving
diazepam (85 %) [43]. The median time to abrogation of
seizure activity was shorter (p \ 0.001) in the valproate
(5 min) than in the diazepam group (17 min). Break-
through seizures during the maintenance phase occurred in
eight patients in each group.
In the study comparing intravenous valproate with
intravenous phenobarbital in children, treatment success
was defined as cessation of all convulsive activity
within 20 min of anticonvulsant infusion [53]. Seizure
termination was significantly higher among patients
treated with intravenous loading of valproate (27 of 30
patients; 90 %) than in patients treated with phenobar-
bital (23 of 30 patients; 77 %) (p = 0.189). In the
phenobarbital group, a statistically significant higher
relapse of SE within 24 h was observed (12 of 23
children) compared with valproate treatment (4 of 27
children).
3.2.2 Comparative Non-Randomized Studies
Four studies have compared the efficacy of intravenous
valproate with that of intravenous phenytoin or leveti-
racetam [48–51].
Table 3 Prospective open-label studies evaluating intravenous valproate monotherapy in the treatment of status epilepticus
References N Patients Type of SE Dose regimen






Initial bolus 25 mg/kg over 30 min
Followed by infusion 100 mg/h for C24 h
Median bolus dose 1,800 mg (range 700–2,500 mg)










Initial bolus 20–40 mg/kg over 1–5 min
Repeated after 10–15 min if necessary
Then 5 mg/kg/h infusion







Initial bolus 15 mg/kg
Followed 30 min later by infusion at 1 mg/kg/h








Initial bolus 15 mg/kg
Followed 30 min later by infusion at 1 mg/kg/h for 24 h
Ramsay et al. [65] 10 Age and gender not
specified
Not specified Bolus infusion 20–30 mg/kg at 0.3–0.5 mg/kg/min





NCSE 900–3,000 mg/24 h infusion over 2 days
Narayanan and Murthy
[44]a






Chen et al. [47] 48 5 children (\15 y) and





Initial bolus of 15 mg/kg over 5 min (repeated 10–15 min
later if necessary), followed by continuous infusion at
30 mg/kg, infused at an hourly rate of 6 mg/kg
a The figures in brackets refer to subjects receiving intravenous valproate monotherapy in studies where more than one AED was studied
EPC epilepsia partialis continua, GMC generalized myoclonic, GTC generalized tonic–clonic, NCSE non-convulsive status epilepticus, PM
partial motor, PMC partial myoclonic, SE status epilepticus, sGTC secondary generalized tonic–clonic, TSE tonic status epilepticus
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One prospective study compared intravenous valproate
with intravenous levetiracetam in adults with refractory SE
at a tertiary center in India [49]. Refractory SE was defined
as seizures lasting for more than 1 h, and patients had to
have already received intravenous lorazepam and phenyt-
oin. Clinical seizure cessation after infusion was obtained
by 26 of 41 patients in the valproate group (68.3 %) and 28
of 41 patients in the levetiracetam group (73.2 %),
although the difference was not statistically significant.
Seizure control was not reached by 13 (31.7 %) patients in
the valproate group and 11 (26.8 %) in the levetiracetam
group (difference not statistically significant), and patients
required intubation and administration of propofol or
midazolam infusion.
One retrospective study was conducted in adults with
convulsive SE who were treated with intravenous valproate
as first- or second-line AED [48]; 12 (24 %) and 37 (76 %)
patients were treated with intravenous valproate and phe-
nytoin as first-line treatment, respectively. Treatment suc-
cess was defined as the cessation of seizures by either
clinical or EEG evidence. SE ceased in 9 of 12 patients
(75 %) with intravenous valproate and 17 of 37 patients
(46 %) with intravenous phenytoin as first-line treatment
(difference not statistically significant), whereas it ceased
Table 4 Retrospective case series evaluating intravenous valproate monotherapy in the treatment of status epilepticus
References N Patients Type of SE Dose regimen
Limdi et al. [39] 63 Age range not specified
30 men/33 women
Not specified Bolus 10–78 mg/kg until serum levels reach
278 mg/l
Czapin´ski [54] 120 (40)a Age and gender not
specified
Not specified Initial bolus 15 mg/kg
Followed by infusion at 1 mg/kg/h
Peters and Pohlmann-
Eden [40]






Bolus infusion 4–16 mg/kg for 5–10 min
Followed by infusion of 0.5–4 mg/kg/h for 4 h to
6 days




Bolus infusion 25 mg/kg
Mean serum concentration 80.1 mg/l
Rosenow and Knake
[35]





Bolus infusion 300–800 mg (mean 1,000 mg)
Followed by infusion of 1,200–1,800 mg/24 h





Initial bolus 20 mg/kg
Followed by infusion at 1 mg/kg/h




Not specified Bolus infusion 25 mg/kg at 2.8 mg/kg/min
Katragadda et al. [32] 12 1 child, 11 adults Partial NCSE: 9
Absence status: 3
Not specified
Price [61] 11 6 children (6–17 y)
5 adults (26–72 y)
7 male/4 female
Not specified Not standardized
Jha et al. [36] 11 2 children (7, 15 y)






Bolus infusion 20 mg/kg at 20 mg/min
Repeated as necessary




Bolus infusion 20 mg/kg at 20 mg/min
Followed by 10 mg/kg every 6 h for 24 h
Short [59] 22 (7)a All ages (2–75 y)
Mean age 40 y
Not specified Mean initial dose: 1,020 ± 946 mg
Mean total dose: 19,017 ± 30,196 mg
Mean infusion rate: 21 ± 13 mg/min
a The figures in brackets indicate the number of subjects receiving intravenous valproate monotherapy
EPC epilepsia partialis continua, GTC generalized tonic–clonic, IG idiopathic generalized, NCSE non-convulsive status epilepticus, SE status
epilepticus, sGCT secondary generalized tonic–clonic, SP simple partial
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in 7 of 20 (35 %) patients who received second-line
valproate.
Kalita et al. [50] conducted a prospective study in
children and adults with convulsive and non-convulsive
SE, comparing first-line intravenous valproate with first-
line intravenous phenytoin. A total of 65 patients received
valproate and 52 received phenytoin as a first-line AED,
which resulted in control of SE in 56 % of patients with
valproate and 44 % of patients with phenytoin. Crossing
over of the treatment in uncontrolled patients resulted in
seizure cessation in 41 additional patients, whereas 35
(30 %) remained refractory to both valproate and phenyt-
oin. Within 24 h, seizures recurred in six patients whose
SE initially responded to the first or second AED (no fur-
ther information on valproate or phenytoin was available in
the published article).
A retrospective study compared intravenous valproate
with phenytoin or levetiracetam as second-line treatment in
adults [51]. The primary outcome was the failure of the
second-line AED, defined as the need to introduce a further
compound to control SE; 15 of 59 patients in the valproate
group (25.4 %) failed to control seizures, compared with
29 of 70 patients in the phenytoin group (41.4 %) and 28 of
58 patients in the levetiracetam group (48.3 %).
3.2.3 Status Epilepticus (SE) Subtypes
Certain studies have reported seizure outcome in response
to intravenous valproate treatment in defined seizure types.
3.2.3.1 Generalized Tonic–Clonic SE The largest group
of patients for whom seizure outcome has been reported by
seizure type corresponds to patients presenting with gen-
eralized tonic-clonic SE. Specific outcome was reported in
ten studies [29, 30, 33, 34, 36, 40, 45, 47, 49, 52], including
a total of 166 patients. Most subjects (119/166) responded
to treatment, yielding an overall response rate of 71.7 %
(95 % CI 68.3–75.1).
3.2.3.2 Focal SE The other type of SE in which intra-
venous valproate has been most frequently evaluated is
simple or complex focal SE. Overall, data have been
reported for 107 patients, included in nine studies [29–31,
33, 34, 36, 45, 47, 57]. Most subjects (83/107) responded to
treatment, with an overall response rate of 77.6 % (95 %
CI 75.3–79.9).
3.2.3.3 Absence Status Information on the effectiveness
of monotherapy with intravenous valproate in absence
status is limited. Such patients have been reported in six
studies [29, 32, 33, 36, 44, 57]. The number of subjects
in these studies was low (16 overall, ranging from one
to five patients per study). In all studies except one [57],
including three patients in whom absence status was
described as atypical, SE was rapidly abrogated by
valproate treatment in the majority of cases (12/16
cases). The overall response rate in absence status was
75.0 % (95 % CI 53.8–96.2). In one study, two patients
with absence status received valproate as first-line
therapy rather than after failure of intravenous benzo-
diazepines [44]. Both of these patients responded to
treatment.
3.2.3.4 Other Presentations of SE Three patients with
myoclonic SE were studied by Giroud et al. [29] and four
such patients by Jha et al. [36]. One patient in each study
failed to respond. The overall success rate was thus 71 %.
Patel and Jha [38] reported ten patients with post-anoxic
myoclonic SE occurring after surgery. SE was abrogated
successfully in six of these patients (60 %) with intrave-
nous valproate given at a dose of 30 (four patients) or 40
(two patients) mg/kg within 2–10 h. In addition to these
patients, two cases of successful treatment of myoclonic SE
have been reported by Sheth and Gidal [63]. U¨berall et al.
[33] reported two cases of status associated with infantile
spasms; both responded successfully to intravenous val-
proate therapy.
3.2.4 Seizure Outcome and Order of Valproate
Administration
Two randomized [41, 46] and one non-randomized [50]
controlled trials used valproate as first-drug antiepileptic
treatment instead of benzodiazepines. Four randomized
[42, 43, 52, 53] and three non-randomized [48, 49, 51]
controlled trials used valproate after failure of first-line
benzodiazepines (lorazepam or diazepam).
Among studies using valproate as second-line drug, SE
was controlled in 50–90 % of patients allocated to val-
proate in randomized controlled studies, and in 56 % of
patients treated with valproate in the non-randomized
controlled trial. Among studies using valproate as first-line
drug, SE was controlled in 66–72.2 % of patients allocated
to valproate in randomized controlled studies, and in
68.3–75 % of patients treated with valproate in non-ran-
domized controlled trials.
3.3 Safety
Information on the safety of intravenous valproate derives
from a limited number of dedicated safety studies,
adverse event reporting in the efficacy studies described
above, individual case reports, and pharmacovigilance
reporting.
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3.3.1 Dedicated Safety Studies
A number of dedicated studies have investigated the safety
of intravenous valproate in patients with epilepsy during
the clinical development of this formulation. Not all of
these studies concern patients with SE, but the data
obtained are nonetheless pertinent to the risk–benefit
assessment of intravenous valproate in SE.
The largest of these studies included 318 patients, both
children and adults, with epilepsy and hospitalized for
seizure-related reasons [64]. The initial dose was 15 mg/
kg/day in four divided doses every 6 h. Subsequent doses
were adjusted at the discretion of participating investiga-
tors as a function of serum valproate concentrations. The
median dose of valproate administered was 375 mg infused
over 1 h. The median number of doses was four, given over
2 days. Transient adverse events were reported in 54
patients (17.5 %), most frequently headache, injection-site
reactions, nausea, somnolence, vomiting, dizziness, and
taste perversion. None were reported in more than seven
patients (2.3 %). No changes in hematological parameters,
blood chemistry, or vital signs were observed.
A second large study compared infusion of valproate at
either 1.5 or 3 mg/kg/min in 112 hospitalized children or
adults with epilepsy [65]. The maximum dose per infusion
permitted was 15 mg/kg, and the maximum number of
infusions per 24 h period was four. The primary outcome
was changes in blood pressure during and after the first
valproate infusion. Although no change in mean blood
pressure was observed in the sample as a whole, two
subjects infused at a rate of 3 mg/kg/min presented tran-
sient hypotension. The most common adverse events
reported were somnolence, paresthesia, dizziness, and
nausea. None of the patients had any alteration of con-
sciousness. A possibly treatment-related case of encepha-
lopathy was reported as a serious adverse event in a patient
receiving valproate at an infusion rate of 3 mg/kg/min
(peak serum valproate concentration of 123 lg/ml), which
resolved upon discontinuation of valproate. No clinically
significant abnormalities in blood chemistry or hematology
were noted.
A number of other smaller safety studies [66–69] have
reported adverse event profiles similar to these two large
studies. In addition, one case of asymptomatic hyperam-
monemia has been described [66]. More recently, a pro-
spective study on 40 patients receiving an intravenous
loading dose of 20 mg or 30 mg at 6 mg or 10 mg/kg/min
of valproate found asymptomatic hyperammonemia in 30
of 40 patients 1 h after the infusion, decreasing to 66 % at
24 h after infusion [70]. None of the patients had any
alteration of consciousness or increase of transaminases.
Concerning more rapid injection schedules, one study
[68] compared blood pressure changes and adverse events
between 36 patients infused at a rate of 3 mg/kg/min up
to a maximum dose of 15 mg/kg, 24 patients infused at
3 mg/kg/min up to 30 mg/kg, and six patients infused at
6 mg/kg/min up to 15 mg/kg. No increase in the incidence
of adverse events was seen with the higher dose or faster
infusion rate, and no changes in blood pressure were
observed. Subsequently, infusion rates of up to 11 mg/kg/min
have been reported in pediatric patients, with no untoward
safety issue being identified [71].
Since hypotension is a concern with other intravenous
AED treatments for SE, such as phenytoin, a retrospective
analysis has been performed of the hemodynamic effects of
intravenous valproate used to control SE in 13 patients with
antecedents of hypotension or cardiovascular instability
[72]; 12 of these patients were elderly ([64 years). The
mean loading dose of intravenous valproate was
25.1 ± 5.0 mg/kg infused at a rate of 36.6 ± 25.1 mg/min,
which produced serum valproate concentrations after
completion of the infusion of 78.7 ± 35.8 mg/l. All except
one patient received vasopressors (dopamine or dobuta-
mine) before the valproate infusion began. No significant
changes in systolic or diastolic blood pressure were
observed during or after valproate infusion, and increases
in vasopressor dose were not required. No other cardio-
vascular adverse effects or changes in cardiac rhythm were
observed.
An open-label, prospective trial evaluated the safety of
rapid intravenous loading of undiluted valproate (20 or
30 mg/kg/min at rates of 6 or 10 mg/kg/min) in 40 patients
with epilepsy [69]. Rapid administration of valproate was
well tolerated, with no significant changes in heart rate
and mean arterial pressure by dose group (20 mg/kg,
30 mg/kg) across time (measurements at 20, 30, 45, 60,
and 240 min after administration). No patient exhibited
alteration of consciousness at 30–60 min after dose
administration compared with baseline, although three
patients (7.5 %) complained of sedation and one of nausea.
There were no disturbances in cardiac conduction or
arrhythmias as indicated by normal electrocardiogram
(ECG) in all patients at all time points. A total of 30
patients (81.5 %) complained of local irritation (pain/
burning or paresthesias) lasting less than 3 min, with no
indication of redness, irritation, or phlebitis. No significant
changes in platelets or hepatic parameters were observed.
Although this study was not conducted in patients with
SE, rapid administration of undiluted valproate proved safe
and well tolerated, supporting its use in emergent
situations.
The risk of local injection-site reactions with intrave-
nous valproate was explored specifically in a retrospective
chart review of two double-blind randomized clinical trials
evaluating the use of valproate or phenytoin to prevent
post-traumatic seizures in 775 patients with traumatic brain
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injury [73]. Injection-site reactions occurred in 18 % of
patients receiving valproate and 25 % of those receiving
phenytoin, for the most part during administration of the
initial loading dose. When only patients receiving the drugs
by a peripheral line were taken into account, the frequency
of injection-site reactions with valproate and phenytoin
was 21 and 30 %, respectively (p = 0.056). No cases of
skin necrosis or purple glove syndrome were observed in
both groups. However, other studies reported an incidence
of purple glove syndrome of 1.7–5.9 % after phenytoin
administration [74, 75].
3.3.2 Comparative Randomized Studies
The six comparative randomized studies included 183
patients treated with valproate. The incidence of hypoten-
sion and respiratory depression was reported in all six
studies, and the incidence of hepatic abnormalities in two
studies. The overall rate of these three adverse events in
patients treated with intravenous valproate was 0.5, 0.5,
and 3.8 %, respectively (Table 5). The incidence of
hypotension and respiratory depression was lower with
valproate than with phenytoin (8.7 and 4.3 %, respectively)
or diazepam (21.4 and 25 %, respectively). Conversely, the
incidence of hypotension was equal to that of intravenous
phenobarbital (0 %), whereas the incidence of respiratory
depression was lower for valproate than that reported for
intravenous phenobarbital (3.3 %). On the other hand, the
incidence of liver abnormalities was higher than that
reported for intravenous phenytoin (2.2 %). Given the low
patient numbers, none of the differences reported in the
individual studies were statistically significant.
A recent systematic review assessing the role of val-
proate in generalized convulsive SE included the studies
comparing intravenous valproate with intravenous phe-
nytoin [41, 42, 46] in a meta-analysis [62]. Compared with
phenytoin, intravenous valproate had a statistically lower
risk of adverse effects (considered as a whole) (RR 0.31,
95 % CI 0.12–0.85).
3.3.3 Comparative Not-Randomized Studies
The four comparative not-randomized studies included 197
patients treated with valproate. The incidence of hypoten-
sion and respiratory depression was reported in only one
study, showing no difference between the drugs (0 %) [49].
3.3.4 Uncontrolled Studies and Case Series
Adverse events reported in the other prospective studies
and retrospective case series discussed above are presented
in Table 6. Interpretation of these studies is limited by the
disparate nature of adverse event reporting between studies
and incomplete ascertainment. Nevertheless, the nature and
frequency of the adverse events described are essentially
similar to what was observed in the dedicated safety
studies. The most frequently reported side effects were
nausea/vomiting, dizziness, and sedation (Tables 7 and 8).
No effects on respiratory function were noted. Cardio-
vascular effects were limited to slight hypotension reported
in five patients overall; this was generally mild and tran-
sient, and effects of co-medication were suspected in some
cases. The local tolerability of intravenous valproate was
also good, with only two subjects reporting injection-site
pain. Mild hyperammonemia and mild thrombocytopenia
were reported in four patients each.
3.3.5 Case Reports
A number of case reports have appeared in the literature
describing idiosyncratic adverse reactions to intravenous
valproate in patients with SE. Several of these have
described cases of encephalopathy. For example, Rossetti
and Bromfield [76] have described two patients developing
acute encephalopathy within 48 h of receiving intravenous
valproate for the treatment of SE. Serum valproate con-
centrations were in the therapeutic range. In these cases,
encephalopathy was associated with hyperammonemia
twofold higher than normal. Symptoms resolved after
reduction of the valproate dose. Embacher et al. [77]
described a woman who developed symptoms of enceph-
alopathy within 24 h of receiving intravenous valproate.
Again, serum valproate levels were not markedly elevated
(29 lg/ml), and serum ammonium was within the normal
range. The patient recovered completely within 48 h of
discontinuation of valproate. Reversible symptoms of
encephalopathy, including confusion or lethargy, were
observed in three adult patients with absence SE treated
with intravenous valproate and who were on maintenance
therapy with lamotrigine [78]. In these patients, the authors
related the symptoms to elevated serum levels of lamotri-
gine due to the well characterized pharmacokinetic inter-
action between valproate and lamotrigine, whereby
valproate inhibits hepatic glucuronidation of lamotrigine.
In addition to these reports of encephalopathy, a case of
significant hypotension following intravenous valproate
infusion was described in an 11-year-old girl presenting
febrile SE following varicella infection and receiving val-
proate at a dose of 30 mg/kg over 1 h [79]. This patient had
previously received 10 mg of diazepam and then 1.6 mg of
lorazepam, shortly before infusion of valproate was initi-
ated in an attempt to control recurrent seizure activity. The
contribution of valproate to the onset of hypotension is
consequently difficult to determine.
Intravenous administration of valproate can be associ-
ated with acute pancreatitis [106] and with hepatic failure.
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A case of acute pancreatitis following intravenous valpro-
ate administration has been reported, as well as a case of
fulminant hepatic failure associated with hemorrhagic
shock leading to death in 9-year-old patient with cerebellar
syndrome and moderate mental retardation receiving
intravenous valproate for the treatment of SE [80]. Four





Definition of ‘responders’ Responders/
Na
% (95 % CI)
Comparative randomized studies
Agarwal et al. [42] Mixed CSE Clinical or EEG seizure cessation within 20 min of
infusion
44/50 88.0 (79–97)
Misra et al. [41] Mixed CSE Clinical seizure cessation after infusion 23/35 65.7 (50–81.4)
Gilad et al. [46] Adults CSE Clinical seizure cessation within 20 min of infusion 13/18 72.2 (51.5–92.9)
Chen et al. [47] Mixed CSE Clinical seizure cessation after infusion 15/30 50.0 (32.1–67.9)
Mehta et al. [43] Children CSE Clinical seizure cessation after infusion 16/20 80.0 (62.5–97.5)
Malamiri et al. [53] Children CSE Clinical seizure cessation after infusion within
20 min of infusion
27/30 90.0 (79.3–100)
Comparative non-randomized studies
Tripathi et al. [49] Adults CSE Clinical seizure cessation after infusion 26/41 68.3 (48.7–78.2)
Tiamkao and Sawanyawisuth
[48]
Adults CSE Clinical seizure cessation within 30 min of infusion 9/12b 75 (50.5–99.5)
7/20b 35 (14.1–55.9)
Kalita et al. [50] Mixed Mixed Clinical seizure cessation after infusion 37/65 56.9 (44.9–69)
Alvarez et al. [51] Adults Mixed No additional AEDs needed for C48 h after clinical
and EEG seizure cessation
44/59 74.6 (63.5–85.7)
Prospective studies
Olsen et al. [45] Adults Mixed Clinical seizure cessation after infusion 31/41 75.6 (62.5–88.8)
U¨berall et al. [33] Children Mixed Clinical seizure cessation after infusion 32/41 78.0 (65.4–90.7)
Giroud et al. [29] Adults Mixed Clinical seizure cessation within 20 min of infusion 19/23 82.6 (67.1–98.1)
Czapin´ski and Terczyn´ski
[30]
Adults CSE Clinical seizure cessation within 30 min of infusion 16/20 80.0 (62.5–97.5)
Ramsay et al. [65] NR NR NR 6/10 60.0 (26.6–90.4)
Leninger and Hofnagel [56] Adults NCSE Clinical seizure cessation after infusion 4/6 66.7 (28.9–104.4)
Narayanan and Murthy [44] Adults NCSE Clinical seizure cessation after infusion 2/2 100
Chen et al. [47] Mixed CSE Clinical seizure cessation within 1 h of the infusion 42/48 87.5 (78.1–96.9)
Retrospective case series
Limdi et al. [39] NR NR No additional AEDs needed for C12 h after clinical
and/or EEG seizure cessation
40/63 63.3 (51.6–75.4)
Czapin´ski [54] NR NR Clinical seizure cessation within 30 min of infusion 33/40 82.5 (70.7–94.3)
Peters and Pohlmann-Eden
[40]
Adults Mixed Clinical seizure cessation within 15 min of infusion 27/35 77.1 (63.2–91.1)
Naritoku [34] NR CSE Clinical seizure cessation after infusion 16/32 50.0 (32.7–67.3)
Rosenow and Knake [35] Adults Mixed NR 12/27 44.4 (25.7–63.2)
Campistol et al. [31] Children CSE Clinical seizure cessation after infusion 11/19 57.9 (35.7–80.1)
Yu et al. [37] Children Mixed Clinical seizure cessation within 20 min of infusion 18/18 100
Katragadda et al. [32] Mixed NCSE NR 9/12 75.0 (50.5–99.5)
Price [61] Mixed NR NR 10/15 66.7 (42.8–90.5)
Jha et al. [36] Mixed Mixed Clinical seizure cessation within 24–48 h of infusion 10/11 90.9 (73.9–107.3)
Patel and Jha [38] Adults CSE Clinical seizure cessation after infusion 6/10 60.0 (29.6–90.4)
Short [59] Mixed NR NR 5/7 71.4 (38–104.9)
a Number of subjects receiving intravenous valproate monotherapy
b 12 and 20 patients received intravenous valproate as the first- and second-line therapy, respectively
AED anti-epileptic drug, CI confidence interval, CSE convulsive status epilepticus, EEG electroencephalography, NCSE non-convulsive status
epilepticus, NR not reported, SE status epilepticus
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months after starting valproate treatment (initially as
polytherapy up to 600 mg/day and later as monotherapy up
to 1,200 mg/day), the child had nausea and vomiting, with
subsequent increasing sleepiness and reduced vigilance.
Laboratory exams revealed severe liver failure. Post-mortal
examinations showed a microvescicular hepatic steatosis
with centro- and mediozonal necrosis, hemoperitoneum,
retroperitoneal bleeding, and hemorrhage involving pan-
creas, adrenal glands, and small bowel. The authors did not
rule out the presence of underlying metabolic disorders
(organic acidemias, mitochondrial disorders, Alper’s
disease).
3.3.6 Pharmacovigilance Data
As of 31 January 2006, a total of 517 medically confirmed
adverse drug reactions in 224 patients receiving intrave-
nous valproate had been reported in the worldwide Sanofi-
Aventis post-marketing pharmacovigilance database since
1994 [81]. Given the estimated exposure to intravenous
valproate over the period ([1 million units prescribed per
year worldwide), the reporting rate for adverse events was
less than one case per 100,000 administrations. It should be
noted that the indication for prescription was not neces-
sarily SE in all these cases, and in many cases the indi-
cation was not reported. SE was explicitly reported as the
reason for prescription in around one-quarter of these
cases. Children, again in all indications, accounted for
21 % of the reported events. The most frequently reported
adverse drug reactions (between ten and 50 reports each)
were hyperammonemia, coma, encephalopathy, metabolic
encephalopathy, thrombocytopenia, confusional state,
pancreatitis, hepatic failure, somnolence, and EEG abnor-
malities. Reporting of these events did not necessarily
imply that a causal relationship to treatment had been
identified. No relevant differences in the distribution of
adverse drug reactions were noted between children and
adults or between patients known to have received treat-
ment for SE and the others.
4 Discussion
The cumulative literature describes the experiences of over
800 patients with various forms of SE treated with intra-
venous valproate. The overall response rate to abrogate SE
Table 6 Adverse event
reporting in six comparative
randomized studies of valproate
in status epilepticus
Study and adverse event Valproate Phenytoin Diazepam Phenobarbital
Agarwal et al. [42]
Hypotension 0/50 6/50
Respiratory depression 0/50 2/50
Mild elevation of liver enzymes 4/50 0/50
Misra et al. [41]
Hypotension 0/35 2/33
Respiratory depression 1/35 2/33
Liver dysfunction 3/35 2/33
Gilad et al. [46]
Cardiac arrhythmia 0/18 1/9
Vertigo 0/18 1/9
Hyponatremia 0/18 1/9
Chen et al. [47]
Hypotension 0/30 2/36
Respiratory depression 0/30 2/36
Liver dysfunction 0/30 0/36
Bone marrow suppression 1/30 0/36
Hyperammonemia 4/30 0/36
Mehta et al. [43]
Hypotension 0/20 10/20
Respiratory depression 0/20 12/20
Malamiri et al. [53]
Hypotension 1/30 0/30
Respiratory depression 0/30 1/30
Lethargy 3/30 17/30
Vomiting 3/30 4/30
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was 70.9 % (95 % CI 67.8 to 73.9). This compares favor-
ably to response rates reported in the Veterans Affairs SE
Cooperative Study [12], which ranged from 43.6 % for
phenytoin to 64.9 % for lorazepam in early SE, and also to
the overall response rates of published literature on intra-
venous levetiracetam, which is around 70 % [19, 20, 82],
and lacosamide, which is 56 % in recent series [21, 22, 83].
Response rates to intravenous valproate were better in
children than in adults and did not differ between the SE
types. In addition, absence seizures, which can be
aggravated by phenytoin, responded well to intravenous
valproate. The most commonly reported effective doses
were between 15 and 45 mg/kg in bolus (6 mg/kg/min)
followed by 1–3 mg/kg/h infusion, although in the literature
higher infusion rates following initial bolus (up to 5 mg/kg/h)
have been reported [33]. The response rates were even
higher in the randomized controlled trials than in the non-
randomized trials and retrospective as well as prospective
open series. This finding is not easy to explain, since usually
non-randomized trials tend to overestimate the treatment
Table 7 Adverse event
reporting in four comparative
non-randomized studies of
valproate in status epilepticus
Study Adverse event Patient numbers in the VPA arm




Tiamkao and Sawanyawisuth [48] Adverse effects not reported
Kalita et al. [50] Adverse effects not reported
Alvarez et al. [51] Adverse effects not reported
Table 8 Adverse event reporting in other clinical studies on valproate in status epilepticus
Study N Main safety findings
Campistol et al. [31] 19 No evidence of important side effects; hyperammonemia, somnolence (two
subjects each); thrombocytopenia/lymphopenia (one subject); no hypotension
Czapin´ski and Terczyn´ski [30] 20 No adverse events in ten subjects; nausea, injection site pain, abdominal pain
(two subjects each); dizziness, taste perversion, somnolence, tremor (one
subject each)
Czapin´ski [54] 40 No safety data reported
Giroud et al. [29] 23 Moderate, transient decrease in heart rate and blood pressure; no respiratory
changes; no local injection reactions
Jha et al. [36] 11 No adverse events reported; no respiratory depression or hypotension
Katragadda et al. [32] 12 Thrombocytopenia in three subjects
Leninger and Hofnagel [56] 6 No safety data reported
Limdi et al. [39] 63 Hypotension in three subjects; no injection-site reactions
Narayanan and Murthy [44] 2 Adverse events not reported by treatment group
Naritoku [34] 10 One case of hyperammonemia; no hypotension
Olsen et al. [45] 41 One case of moderate hypotension; no other side effects observed
Patel and Jha [38] 10 No adverse events reported
Peters and Pohlmann-Eden [40] 35 No severe side effects; mild side effects in seven subjects (dizziness, skin
reaction, nausea, fatigue, tremor); no hypotension
Price et al. [61] 11 One case of thrombocytopenia
Ramsay et al. [65] 10 No cardiovascular, hematological, or subjective side effects
Rosenow and Knake [35] 27 No adverse events reported
Short [59] 7 Hyperammonemia in one subject; sedation and hypotension in two subjects
U¨berall et al. [33] 41 No drug-related systemic or local side effects. No biological changes
Yu et al. [37] 18 No significant changes in heart rate or blood pressure; one case of transient
tremor
Chen et al. [47] 48 No evidence for valproate-related systemic or local side effects
Tiamkao and Sawanyawisuth [48] 32 Adverse effects not systematically reported
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effect [84]. Two other facts may have contributed to this: in
a recent meta-epidemiological study on 139 meta-analyses,
trials from less developed countries showed more favorable
treatment effects than those in developed countries [85].
Three of the six randomized studies using valproate for SE
came from India, one from China, and one from Iran, the
latter having the highest response rates (90 %). In addition,
the etiology, which is recognized as an important predictor
of outcome [86, 87], is different from that of the more
developed countries, with some of the causes more likely to
be easy to control [88–91].
A recent systematic review compared the relative effi-
cacy of five AEDs (valproate, lacosamide, levetiracetam,
phenobarbital, phenytoin) in treatment of benzodiazepine-
resistant convulsive SE [107]. A dichotomous outcome
analysis of a single group estimate was performed for each
AED with regards to cessation of seizure activity. The
efficacy of valproate was higher (75.7 %; 95 % CI
63.7–84.8) than that of other AEDs (lacosamide: analysis
not performed due to insufficient data; levetiracetam:
68.5 %, 95 % CI 56.2–78.7; phenobarbital 73.6 %, 95 %
CI 58.3–84.8; phenytoin 50.2 %, 95 % CI 34.2–66.1).
Considered overall, cumulative data from the literature are
therefore consistent with valproate being a safe and
effective therapeutic option for patients with established
SE who have previously failed conventional first-line
treatment with benzodiazepines. However, it is important
to consider that the methodological heterogeneity of the
source literature makes the cumulative response rate
reported in our review and previous systematic reviews a
relatively imprecise result. Limiting the methodological
heterogeneity across studies will be of utmost importance
in further research in the treatment of SE: investigators
should adopt uniform definitions of SE and its different
stages, provide individual patient data, and report their
results clearly and explicitly [62].
Studies of the safety of intravenous valproate adminis-
tration in patients with SE showed a low incidence of
adverse events overall (\10 %) mainly dizziness, throm-
bocytopenia, and mild hypotension), which was indepen-
dent of infusion rates [65, 67, 69, 92]. There were no
unexpected side effects compared with the known safety
profile of valproate in other indications using oral admin-
istration. The low overall incidence of adverse events fol-
lowing infusion, especially the good cardiovascular and
respiratory tolerability even in high doses and fast infusion
rates up to 30 mg/kg at 10 mg/kg/min [69], of intravenous
valproate observed in these studies is all the more note-
worthy in that the patients often had multiple morbidities
and in some cases had recently received, or were still
receiving, other AEDs.
The most serious concern relates to the possibility
of acute encephalopathy, sometimes related to hepatic
abnormalities or hyperammonemia. This idiosyncratic
effect may occur when serum valproate concentrations are
in the normal therapeutic range (50–110 lg/ml). However,
the number of reported cases is relatively low, and most
seem reversible on reduction of the dose of valproate or
interruption of treatment. In any case, continued or regular
periodic monitoring of the EEG during the stabilization
period is desirable for all patients with SE [93], and this
can be exploited to detect possible encephalopathy at an
early stage. Furthermore, clinicians should monitor lipase,
amylase (risk of pancreatitis), ammonium, and transami-
nase levels. Given the potentially serious or even fatal
consequences of not abrogating seizure activity rapidly in
SE, the ratio of benefit to risk seems clearly in favor of
treatment. Pre-treatment with barbiturates, topiramate, or
combinations of both may increase the risk of acute
encephalopathy [94–98]. The mechanisms leading to acute
encephalopathy are not well understood, but hitherto
unrecognized mitochondrial dysfunction may play a crucial
role [77, 99]. Thus, valproate should be used with caution
in unexplained SE in children.
Intravenous valproate has several other potential
advantages for use as a treatment for established SE.
Unlike phenytoin and phenobarbital, it does not require
organic solvents for dissolution, minimizing the risk of
injection-site reactions such as ‘purple glove’. Thus, val-
proate can be injected at a physiological pH without
incompatibility with other commonly used intravenous
solutions. The pharmacokinetics of valproate is well
characterized [100], and the transition from intravenous to
oral therapy can be made smoothly once SE has been
controlled and the patient returns to the community [101].
Finally, valproate is a broad-spectrum AED that can be
used effectively in virtually all types of epilepsy, and safely
in patients whose seizure type is poorly characterized [101,
102]. As such, it would potentially be of particular interest
in, for example, absence status, where phenytoin is
contraindicated.
Acute treatment of SE is responsible for a high pro-
portion of hospital costs associated with epilepsy. A
pharmacoeconomic study conducted in Germany (popula-
tion 82 million) evaluated that SE causes hospital costs of
more than €83 million each year, around one-quarter of the
total of epilepsy-related inpatient treatment costs (€342
million); these costs far exceed those for a newly estab-
lished diagnosis of epilepsy (€49 million) [108]. Although
to date no single study has performed a formal assessment
of intravenous valproate treatment versus hospital admis-
sion and stay, it is reasonable to hypothesize that prompt
seizure control may result in lower economic burden to the
healthcare system. However, comparative studies are
required to determine which AED has the more favorable
efficacy/safety/cost profile in the treatment of SE.
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5 Conclusions
Intravenous valproate appears to be an effective and safe
therapeutic option for patients with established SE who
have previously failed conventional first-line treatment
with benzodiazepines. However, to inform clinical decision
making appropriately, a randomized controlled trial com-
paring the available treatment options in established SE is
needed. Starting from the 2nd London Innsbruck Collo-
quium of Status Epilepticus [103], a trial protocol has been
presented and subsequently developed by a group of
researchers from the USA and Europe [104, 105]. Once the
tribulations of funding this study are overcome, results can
be expected in a few years from now.
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